January 12, 2017
MHLW Pharmaceutical Management Director Tomonori Nakayama The Ministry of Health, Labor and Welfare (MHLW) is considering applying a proposed four-times-yearly price review scheme for indication-added drugs based on the patient numbers and sales figures projected for their new indications, instead...read more